Nautilus Neurosciences

Nautilus Neurosciences is a specialty pharmaceutical company providing products and services for the treatment of neurological disorders.

Nautilus Neurosciences is a neurology-focused specialty pharmaceutical company committed to providing the healthcare community with relevant products and services that directly benefit those affected by neurological disorders. In the first half of 2010, Nautilus intends to launch a novel product, CAMBIA� (diclofenac potassium for oral solution). Nautilus is backed by Tailwind Capital, a leading private equity firm that invests in health care, business services and media/communications companies.